NCT01520389View on ClinicalTrials.gov

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions
Advanced Solid TumorsColorectal CancerSquamous Cell Head and Neck CancerNon Small Cell Lung CancerTriple Negative Breast Cancer
Interventions
DRUG

MM-151

MM-151

DRUG

MM-151 + irinotecan

MM-151 + irinotecan

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

47905

Horizon Oncology Research, Inc., Lafayette

78229

South Texas Accelerated Research Therapeutics, LLC (START), San Antonio

80045

University of Colorado Denver, Aurora

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT01520389 - Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | Biotech Hunter | Biotech Hunter